11 May 2022 - NICE has published evidence based recommendations on the use of avelumab for adults with locally advanced or metastatic urothelial cancer after the use of platinum-based chemotherapy.

Avelumab is recommended as an option for the maintenance treatment of adults with locally advanced or metastatic urothelial cancer that has not progressed after platinum-based chemotherapy only if:

• Avelumab is stopped at five years of uninterrupted treatment or earlier if the disease progresses
• Merck Serono provides avelumab according to the commercial arrangement

Read NICE technology appraisal guidance